Cytek Biosciences, Inc.
CTKB
$3.77
-$0.05-1.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -6.02M | -10.16M | -17.56M | -11.51M | -12.15M |
| Total Depreciation and Amortization | 10.49M | 10.17M | 9.92M | 9.89M | 9.23M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.20M | 23.51M | 22.22M | 20.36M | 18.71M |
| Change in Net Operating Assets | 7.71M | 9.37M | 846.00K | -12.36M | -10.51M |
| Cash from Operations | 25.38M | 32.89M | 15.43M | 6.38M | 5.28M |
| Capital Expenditure | -3.53M | -4.13M | -4.45M | -4.71M | -4.65M |
| Sale of Property, Plant, and Equipment | 288.00K | 97.00K | 76.00K | -- | -- |
| Cash Acquisitions | -471.00K | -236.00K | -237.00K | -237.00K | -45.13M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -79.27M | 13.80M | 73.07M | 74.17M | -44.11M |
| Cash from Investing | -82.97M | 9.53M | 68.46M | 69.23M | -93.89M |
| Total Debt Issued | 4.18M | 1.40M | 1.39M | 1.39M | -- |
| Total Debt Repaid | -557.00K | -558.00K | -556.00K | -558.00K | -565.00K |
| Issuance of Common Stock | 2.72M | 3.11M | 3.41M | 3.63M | 3.32M |
| Repurchase of Common Stock | -22.17M | -49.89M | -46.37M | -44.66M | -44.57M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -15.82M | -45.94M | -42.13M | -40.20M | -41.81M |
| Foreign Exchange rate Adjustments | 4.53M | 2.19M | 4.61M | 1.34M | -1.45M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -68.89M | -1.33M | 46.37M | 36.75M | -131.87M |